Northside Hospital Cancer Institute

Northside Hospital Cancer Institute
Atlanta, Georgia

Northside Hospital Cancer Institute offers the best of both worlds: clinical excellence on par with academic-based programs, along with the personalized and attentive care typically associated with a community hospital. Northside, which has been offering cancer care services since 1978, is one of the largest and most respected providers of cancer care services in the Southeast.


  • The Blood & Marrow Transplant Program at Northside Hospital has ranked #1 in the United States for the third consecutive year, for having the best survival rates for matched related and unrelated donors (MUD) /allogeneic transplants.
  • More cases of breast cancer and gynecologic (cervical, ovarian and uterine) cancer are diagnosed and treated than at any other hospital in the Southeast.
  • More prostate cancer treatments are performed at Northside than at any other hospital in Atlanta
  • Fully accredited by the American College of Surgeons Commission on Cancer.
    Northside also received an Outstanding Achievement Award.

Our renowned program also consists of palliative care, cancer genetics, screenings, research, support and survivorship.

(404) 851-8000
www.northside.com

Treatment Sites in Georgia

Clinical Trials in Georgia

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type: Multiple Primaries
Study Coordinator: Stacey Brown - 404-851-8238


A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Cancer Type: Leukemia
Study Coordinator: Stacey Brown - 404-851-8238


A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101)
Cancer Type: Leukemia
Study Coordinator: Stacey Brown - 404-851-8238


A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Cancer Type: Leukemia
Study Coordinator: Stacey Brown - 404-851-8238


A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202)
Cancer Type: Bladder Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Non-Hodgkin Lymphoma, Oral Cancer, Ovarian Cancer
Study Coordinator: - 404-303-3355


A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type: Unknown Primary

A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type: Melanoma
Study Coordinator: Marti Sears - 404-303-3355


A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, in Patients With Advanced Melanoma
Cancer Type: Melanoma
Study Coordinator: Marti Sears - 770-496-5555 x5550


A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Women With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received at Least Three Previous Chemotherapy Regimens
Cancer Type: Ovarian Cancer
Study Coordinator: Jen Cuvo - 404-236-8304


A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Cancer Type: Leukemia
Study Coordinator: Stacey Brown - 404-851-8238


A Phase 2, Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Cancer Type: Hodgkin Lymphoma
Study Coordinator: Chuck Sykes - 404-303-3355


A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract
Cancer Type: Unknown Primary
Study Coordinator: Stacey Brown - 404-851-8238


A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Cancer Type: Ovarian Cancer
Study Coordinator: Jen Cuvo - 404-303-3355


A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type: Unknown Primary
Study Coordinator: Anila Lokhandwala - 404-303-3355


A Phase I/IB Study of Ipilimumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Cancer Type: Non-Hodgkin Lymphoma
Study Coordinator: Stacey Brown - 404-851-8238


A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-236-8095


A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Cancer Type: Endometrial Cancer
Study Coordinator: Jen Cuvo - 404-236-8304


A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma
Cancer Type: Bone and Soft Tissue (including Sarcoma)
Study Coordinator: Anila Lokhandwala - 404-303-3355


A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) , Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL
Cancer Type: Leukemia
Study Coordinator: Stacey Brown - 404-851-8238


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: Michelle Smith - 404-303-3355


A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Cancer Type: Acute Lymphoblastic Leukemia, Leukemia
Study Coordinator: Stacey Brown - 404-851-8238


A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Germ Cell Tumor, Ovarian Cancer
Study Coordinator: Jen Cuvo - 404-236-8304


A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-236-8095


A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Cancer Type: Melanoma
Study Coordinator: Marti Sears - 770-496-5555 x5550


A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-236-8095


A Randomized Double-blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Cancer Type: Non-Hodgkin Lymphoma

A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma with Nivolumab and Lenalidomide +/- MILs in the Relapse Setting
Cancer Type: Multiple Myeloma
Study Coordinator: Stacey Brown - 404-851-8238


A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Cancer Type: Endometrial Cancer
Study Coordinator: Jen Cuvo - 404-236-8304


A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Cancer Type: Breast Cancer

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients with Residual Triple-Negative Basal-like Breast Cancer following Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-236-8095


A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-236-8095


A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Melanoma, Unknown Primary

A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-236-8095


A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Cancer Type: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia
Study Coordinator: Stacey Brown - 404-851-8238


A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Cancer Type: Bone and Soft Tissue (including Sarcoma)
Study Coordinator: Anila Lokhandwala - 404-303-3355


A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-303-3355


Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer
Study Coordinator: Michelle Smith - 404-303-3355


An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Cancer Type: Unspecified
Study Coordinator: Stacey Brown - 404-851-8238


Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)
Cancer Type: Multiple Myeloma
Study Coordinator: Stacey Brown - 404-851-8238


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: - 404-303-3355


Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for Patients 60-75 Years of Age With Secondary AML
Cancer Type: Unspecified
Study Coordinator: Stacey Brown - 404-851-8238


Genomics of Young Lung Cancer Study
Cancer Type: Lung Cancer
Study Coordinator: Karen Devine - 404-303-3355


monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-303-3355


Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Stable or Slowly Progressing Disease.
Cancer Type: Melanoma
Study Coordinator: Marti Sears - 770-496-5555 x5550


Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Cancer Type: Multiple Myeloma
Study Coordinator: Stacey Brown - 404-851-8238


Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Cancer Type: Breast Cancer, Ovarian Cancer

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Cancer Type: Lung Cancer
Study Coordinator: Anila Lokhandwala - 404-303-3355


Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-303-3355


Phase II Randomized Study of Paclitaxel and Carboplatin Versus Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Patients With Advanced or Recurrent Sex Cord-Stromal Tumors of the Ovary
Cancer Type: Ovarian Cancer
Study Coordinator: Jen Cuvo - 404-236-8304


Phase II Randomized Study of Whole-Brain Radiotherapy With Versus Without Lapatinib Ditosylate in Patients With Brain Metastasis From HER2-Positive Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-303-3355


Phase III Randomized Study of Diet and Physical Activity Modification Versus Usual Care in Patients With Previously Treated Stage II, III, or IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer
Study Coordinator: Jen Cuvo - 404-236-8304


Protocol For A Research Database For Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries
Cancer Type: Hematologic Malignancies
Study Coordinator: Stacey Brown - 404-851-8238


Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer
Study Coordinator: Michelle Smith - 404-303-3355


Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-303-3355


Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: Renee Gaiter - 770-205-5292 x5


Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Susan Coples - 404-236-8095


S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355